论文部分内容阅读
目的:探讨瑞舒伐他汀对高胆固醇血症患者的降脂疗效及对血管内皮舒张功能(FMD)的影响。方法:选择我院92例高胆固醇血症患者作为实验组并给予瑞舒伐他汀治疗,另选择同期来我院参加健康体检的健康志愿者42例作为对照组,检测治疗前(T0),以及治疗1个月(T1)、2个月后(T2)的血脂水平及肱动脉FMD和非依赖性血管内皮舒张功能(NMD),并对其治疗的不良反应情况进行统计分析。结果:治疗前,实验组患者血浆中TC、TG和LDL-C水平明显高于对照组,而HDL-C水平显著低于对照组,且差异均具有统计学意义(P<0.05)。相对于T0,实验组患者T1和T2血浆中TC、TG和LDL-C水平明显下降,而HDL-C水平显著升高,且差异均具有统计学意义(P<0.05)。患者T2时血浆中TC和LDL-C水平明显低于T1的水平(P<0.05),而TG和HDL-C水平与T1之间的差异无统计学意义(P>0.05);治疗前,实验组患者的FMD值明显低于对照组的健康志愿者(P<0.05)。经过瑞舒伐他汀干预2个月后,实验组患者T2时FMD值明显高于T0(P<0.05),而T2的NMD与T0之间的差异无统计学意义(P>0.05);治疗期间并未出现严重的不良反应。结论:瑞舒伐他汀对老年高胆固醇血症患者降脂效果显著,且有改善FMD的作用。
Objective: To investigate the effects of rosuvastatin on lipid-lowering efficacy and vascular endothelial relaxation (FMD) in patients with hypercholesterolemia. Methods: 92 patients with hypercholesterolemia in our hospital were selected as the experimental group and received rosuvastatin. In the same period, 42 healthy volunteers who participated in the physical examination in our hospital were selected as the control group, and T0, The levels of lipid and brachial artery FMD and non-dependent vascular end diastolic function (NMD) were measured at 1 month (T1), 2 months (T2) after treatment, and their adverse reactions were analyzed statistically. Results: Before treatment, TC, TG and LDL-C levels in plasma of experimental group were significantly higher than those of control group, while HDL-C level was significantly lower than that of control group (P <0.05). Compared with T0, the levels of TC, TG and LDL-C in T1 and T2 plasma in experimental group were significantly decreased, while the levels of HDL-C were significantly increased in experimental group (P <0.05). The levels of TC and LDL-C in plasma at T2 were significantly lower than those at T1 (P <0.05), while there was no significant difference between TG and HDL-C levels and T1 (P> 0.05). Before treatment, The FMD of the patients in the group was significantly lower than that of the healthy volunteers in the control group (P <0.05). After 2 months of intervention with rosuvastatin, the FMD in experimental group was significantly higher than that in T0 (P <0.05), while there was no significant difference in T2 between NMD and T0 (P> 0.05) No serious adverse reactions occurred. Conclusion: Rosuvastatin has significant effects on lipid lowering in elderly patients with hypercholesterolemia, and has the effect of improving FMD.